Sales 2024 * | 55.14B 50.64B 4,598B | Sales 2025 * | 58.11B 53.37B 4,846B | Capitalization | 285B 262B 23,795B |
---|---|---|---|---|---|
Net income 2024 * | 7.74B 7.11B 645B | Net income 2025 * | 10.64B 9.78B 888B | EV / Sales 2024 * | 6.15 x |
Net Debt 2024 * | 53.62B 49.25B 4,471B | Net Debt 2025 * | 47.29B 43.43B 3,944B | EV / Sales 2025 * | 5.72 x |
P/E ratio 2024 * |
31.4
x | P/E ratio 2025 * |
24.1
x | Employees | - |
Yield 2024 * |
3.83% | Yield 2025 * |
4.02% | Free-Float | 96.37% |
Latest transcript on AbbVie
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 01/13/01 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 01/13/01 |
Robert Michael
PSD | President | 53 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 01/13/01 |
Edward Rapp
BRD | Director/Board Member | 66 | 01/13/01 |
Director/Board Member | 70 | 01/13/01 |
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B | |
+0.89% | 124B |